Clinical studies for AB Science's all-purpose anti-inflammatory drug grind to a halt as company flags potential risk of heart disease
When AB Science claimed a breakout win in Alzheimer’s disease for masitinib, its all-purpose tyrosine kinase inhibitor, in late December, CEO Alain Moussy pointed Endpoints News to safety data across thousands of patients as a key strength of the program — which has seen its share of setbacks and regulatory scorn over the years.
“We have a remarkable safety database of co-morbidities in every direction and we feel extremely strong on the safety side because we have exposed so many patients,” he said in an interview then.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.